Current Report · Items 2.01, 7.01, 9.01 · 8-K

Edgewise Therapeutics, Inc.

EWTXNASDAQEQUITYCurrent

Completion of Acquisition or Disposition of Assets · Regulation FD Disclosure

Filed Jul 13, 2026Accepted Jul 13, 2026, 8:37 AM EDTCIK 1710072Accession 0001104659-26-082902

Company context

Edgewise Therapeutics is a leading biopharmaceutical company focused on novel, muscle-targeted therapeutics. Leveraging its expertise in muscle biology and small molecule drug development, Edgewise is advancing a cardiovascular pipeline targeting significant unmet needs, including hypertrophic cardiomyopathy, heart failure and other serious cardiovascular and cardiometabolic conditions. To learn more, go to edgewisetx.com or follow Edgewise on LinkedIn, X, Facebook and Instagram.

Current securities

EWTXNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 2.01, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.01Item 2.01 - Completion of Acquisition

Item 2.01 Completion of Acquisition or Disposition of Assets On July 10, 2026, Edgewise Therapeutics, Inc. (the “Company”) completed the previously announced acquisition of the Company’s sevasemten compound and certain other related assets collectively constituting the Company’s muscular dystrophy program (the “Program”) by Servier Pharmaceuticals LLC and Les Laboratoires Servier (together, the “Buyers”, and such transaction, the “Transaction”), pursuant to the terms and conditions of the previously announced Asset Purchase Agreement by and among the Company and the Buyers. The Buyers acquired the Program for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The Transaction was completed on the terms described in the Company’s Current Report on Form 8-K filed on June 1, 2026.

Item 7.01Item 7.01 - Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On July 13, 2026, the Company issued a press release announcing the completion of the Transaction. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information set forth under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Filed exhibits (1)

EX-99.1 (by filename) tm2620181d1_ex99-1.htm

EX-99.1 2 tm2620181d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 NEWS RELEASE Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline - Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones - - Transaction creates strategically focused cardiovascular company - - Upfront proceeds expected to fully fund EDG-7500 development through potential approval - Boulder, Colo., ( July 13, 2026 ) - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced the successful completion of its previously announced definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, acquired sevasemten and Edgewise’s muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction meaningfully strengthens Edgewise’s balance sheet, providin…

Open exhibit ↗